Comparative effectiveness of adipose-derived mesenchymal stromal cells in the management of knee osteoarthritis: A meta-analysis

Figure 1 PRISMA flow diagram of the included studies.

Figure 2 Methodological quality and risk of bias assessment of all the included studies.

Figure 3 Forest plot of the included studies comparing adipose tissue and bone marrow as a source of mesenchymal stromal cell therapy compared to their controls. A: Visual analog scale (VAS) at 6 mo; B: VAS at 12 mo; C: VAS at 24 mo; D: Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) at 6 mo; E: WOMAC at 12 mo; F: Lysholm at 12 mo; G: Lysholm at 24 mo; H: Knee osteoarthritis outcome score at 12 mo; I: Magnetic resonance observation of cartilage repair tissue score at 12 mo. CI: Confidence interval; NA: Not available.

Figure 4 Pain reduction potential of adipose tissue and bone marrow at various timepoints based on visual analog scale score. ^aP < 0.05; ^bP < 0.001. VAS: Visual analog scale.

Figure 5 Forest plot of the included studies comparing adverse events upon using adipose tissue and bone marrow as a source of mesenchymal stromal cell therapy compared to their controls. CI: Confidence interval.

Figure 6 Publication bias assessment. A: Funnel plot; B: Quantile plot for the visual analog score outcome at 6 mo in the included studies. CES: Combined effect size.